Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study.

Journal of Substance Abuse Treatment
Raj K S Badhan, Rosalind Gittins

Abstract

Methadone use for the management of opioid dependency during pregnancy is commonplace. Methadone levels are altered during pregnancy due to changes in maternal physiology. Despite this, a paucity of data exist regarding the most appropriate optimal dosing regimens during pregnancy. This study applied a pharmacokinetic modeling approach to examine gestational changes in R- and S-methadone concentrations in maternal plasma and fetal (cord) blood. This study did so to derive a theoretical optimal dosing regimen during pregnancy, and to identify the impact of Cytochromes P450 (CYP) 2B6 and 2C19 polymorphisms on methadone maternal and fetal pharmacokinetics. The study noted significant decreases in maternal R- and S-methadone plasma concentrations during gestation, with concomitant increases in fetal levels. At a dose of 90 mg once daily, 75% (R-) and 94% (S-) of maternal methadone trough levels were below the lower therapeutic window at term (week 40). The developed optimal dosing regimen escalated doses to 110 mg by week 5, followed by 10 mg increments every 5 weeks up to a maximum of 180 mg once daily near term. This increase resulted in 27% (R-) and 11% (S-) of subjects with trough levels below the lower therapeutic window at te...Continue Reading

References

Mar 1, 1975·American Journal of Obstetrics and Gynecology·G BlinickR C Wallach
Jun 1, 1976·The Journal of Pediatrics·T S Rosen, C E Pippenger
Apr 1, 1987·Clinical Pharmacology and Therapeutics·C E InturrisiK M Foley
Jan 1, 1993·European Journal of Clinical Pharmacology·K WolffR Calvert
Jun 1, 1996·Therapeutic Drug Monitoring·K KristensenP Sjøgren
Oct 28, 1997·Journal of Human Lactation : Official Journal of International Lactation Consultant Association·B GeraghtyE L Weiss
Apr 21, 1998·Obstetrics and Gynecology Clinics of North America·K KaltenbachL Finnegan
May 8, 1999·British Journal of Clinical Pharmacology·D J FosterF Bochner
Jun 26, 1999·British Journal of Clinical Pharmacology·A Rostami-HodjeganG T Tucker
Jan 13, 2000·Journal of Addictive Diseases·M A JarvisS H Schnoll
May 23, 2001·Heart·S C Siu, J M Colman
Jul 14, 2001·Clinical Pharmacology and Therapeutics·D W BoultonC L DeVane
Jun 5, 2003·Pediatrics·Barbara L PhilippSusan O'Brien
Jul 17, 2004·British Journal of Clinical Pharmacology·Ola DaleEvan D Kharasch
Aug 24, 2004·Archives of Disease in Childhood. Fetal and Neonatal Edition·C A KuschelR S H Rowley
Dec 14, 2004·Biochemical Pharmacology·Ilona A NekhayevaMahmoud S Ahmed
Feb 8, 2005·American Journal of Obstetrics and Gynecology·Timothy S TracyUNKNOWN National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units
Apr 29, 2005·Journal of Pharmaceutical Sciences·Trudy RodgersMalcolm Rowland
Sep 10, 2005·American Journal of Obstetrics and Gynecology·John J McCarthyBarbara Anania
Nov 2, 2005·European Journal of Clinical Pharmacology·Kim WolffDuncan Raistrick
Jul 11, 2006·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·T KiserudS Rasmussen
Sep 21, 2006·Clinical Pharmacokinetics·Andrea N EdgintonStefan Willmann
Feb 6, 2008·Journal of Substance Abuse Treatment·Hendree E JonesGabriele Fischer
Feb 23, 2008·Anesthesiology·Rheem A TotahEvan D Kharasch
Sep 5, 2008·The American Journal on Addictions·Hendrée E JonesMichelle Tuten
Nov 4, 2008·American Journal of Obstetrics and Gynecology·Susie LimLeandro Cordero
Feb 24, 2009·Drug and Alcohol Dependence·Evan D KharaschPamela Sheffels Bedynek
Aug 20, 2009·Current Drug Metabolism·Petr PavekFrantisek Staud
Apr 22, 2010·Journal of Addictive Diseases·Mary Jeanne KreekBrenda Ray
Sep 10, 2010·Basic & Clinical Pharmacology & Toxicology·Yan ChangDavid E Moody
May 20, 2011·Substance Abuse Treatment, Prevention, and Policy·Kenneth M Dürsteler-MacFarlandSylvie A Petitjean
Jul 12, 2011·Journal of Substance Abuse Treatment·Brittany AlbrightWilliam Rayburn
Mar 1, 2008·Journal of Addiction Medicine·Gary D Helmbrecht, Siva Thiagarajah
Jun 1, 2008·Journal of Addiction Medicine·Hendrée E JonesLorraine Milio

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Canadian Journal of Hospital Pharmacy
Jennifer R Shiu, Mary H H Ensom
NIDA Research Monograph
M A Jarvis, S H Schnoll
Neurotoxicology and Teratology
Trecia A Wouldes, Lianne J Woodward
The Journal of Pharmacology and Experimental Therapeutics
S M PondN L Benowitz
© 2021 Meta ULC. All rights reserved